Active black fungus cases at 27,142: Union Minister Mansukh Mandaviya

The country is prepared to increase the availability of Amphotericin B and other drugs used in the treatment of the disease: Mandaviya

black fungus, infection, coronavirus, covid
Press Trust of India New Delhi
2 min read Last Updated : Jun 18 2021 | 6:06 PM IST

India has 27,142 active cases of Mucormycosis, also known as black fungus, and if the number rises, the country is prepared to increase the availability of Amphotericin B and other drugs used in the treatment of the disease, Union Minister Mansukh Mandaviya said on Friday.

"On June 16, 2021, active cases of Mucormycosis were 27,142. Even in the future, if cases of Black fungus increases , India is prepared to have more than sufficient availability of Amphotericin B and other drugs which are required to treat patients of Mucormycosis," Mandaviya said in a tweet.

The Minister of State for Chemicals and Fertilisers noted that domestic production of Amphotericin B has already gone up five folds so far.

"Domestic production of Liposomal Amphotericin B was just 62,000 vials in April, 2021 and now it is expected to cross 3.75 lakh vials in June, 2021," Mandaviya said.

While increasing the domestic production, the government has also placed an order to import 9,05,000 Liposomal Amphotericin B vials, he added.

"India is leaving no stone unturned to boost the availability of Amphotericin B drugs in the country," Mandaviya noted.

The Department of Pharmaceuticals has allocated total 7,28,045 vials of Liposomal Amphotericin B to all the states and central institutions till June 17, 2021, he added.

Amphotericin B is used for the treatment of Mucormycosis.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :diseasesMansukh Lal Mandaviya

First Published: Jun 18 2021 | 6:06 PM IST

Next Story